PCRX - Latest News

Pacira BioSciences, Inc. (PCRX), operates in Healthcare / Drug Manufacturers - Specialty & Generic, trades on NASDAQ.

Market capitalization stands near $906.3M. Trailing twelve-month P/E ratio is 181.44. Beta to the broader market is 0.32.

The article list below shows the most recent PCRX headlines from major financial news vendors. For options traders, the most actionable items are earnings releases, analyst rating changes, M&A activity, and regulatory filings - each can drive a meaningful repricing of implied volatility and shift dealer hedging flow. Pair the news context with the implied-volatility skew and gamma exposure views to see whether the options market has already priced in the headline.

Recent PCRX Headlines

DOMA Perpetual Issues & Mails Letter to Shareholders of Pacira BioSciences - Along with its Definitive Proxy Statement & WHITE Proxy Card - Urging Shareholders to Vote "FOR" DOMA's Three Highly Qualif

gurufocus.com - May 13, 2026

DOMA Perpetual Issues and Mails Letter to Shareholders of Pacira BioSciences - Along with its Definitive Proxy Statement and WHITE Proxy Card - Urg

DOMA Perpetual Issues & Mails Letter to Shareholders of Pacira BioSciences - Along with its Definitive Proxy Statement & WHITE Proxy Card - Urging Shareholders to Vote "FOR" DOMA's Three Highly Qualified, Independent Board Candidates

prnewswire.com - May 13, 2026

DOMA Perpetual Believes the Board and Management are Committing Gross Negligence by Misleading Investors About the True Risks the Business Faces; DOMA

Pacira BioSciences to Participate in Fireside Chats at Three Upcoming Healthcare Conferences

globenewswire.com - May 13, 2026

BRISBANE, Calif. , May 13, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc.

Pacira BioSciences Sends Letter to Stockholders Reiterating Superior Qualifications of its Board Nominees

globenewswire.com - May 12, 2026

Highlights Nominees' Robust Skillsets and Extensive Experience in Healthcare and Biopharmaceuticals Urges Stockholders to Vote “ FOR ” the Election of

Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

globenewswire.com - May 8, 2026

BRISBANE, Calif. , May 08, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc.

How News Affects PCRX Options Pricing

Headlines and scheduled events drive implied volatility in two distinct ways. Pre-event, IV typically inflates as uncertainty about the outcome rises; this is the implied-volatility expansion that creates the long-vol setup. Post-event, IV typically contracts sharply as uncertainty resolves; this is IV crush, which makes premium-selling structures profitable when they survive the underlying move. The size of the crush depends on how stretched pre-event IV is relative to the realized move. Track PCRX's implied vs realized volatility over the news cycle to size pre-event vs post-event positioning. For ticker-level dealer positioning context, the gamma exposure view shows whether dealers are positioned to amplify or dampen post-news moves.

Frequently asked PCRX news questions

What is the latest PCRX news headline?

The most recent PCRX headline (May 13, 2026) is "DOMA Perpetual Issues & Mails Letter to Shareholders of Pacira BioSciences - Along with its Definitive Proxy Statement & WHITE Proxy Card - Urging Shareholders to Vote "FOR" DOMA's Three Highly Qualif". The five most recent stories with summaries and publication times are listed above, sourced from major financial news vendors.

How fresh is the PCRX news on this page?

News rows refresh roughly every 30 minutes during the trading day. The five most recent headlines are listed in publication-time order. Press releases from the company itself typically appear within minutes of the wire release; third-party reporting may lag by 30-60 minutes depending on the source.

What PCRX news moves options pricing?

Three categories move single-name IV most aggressively: scheduled earnings releases (priced into pre-event IV, crushed post-event), unscheduled M&A or strategic announcements (rapid IV expansion, slower decay), and regulatory or legal events (drug-trial readouts, antitrust filings, FDA approvals). Routine news flow (analyst commentary, sector rotation) typically does not move IV meaningfully unless it triggers a cluster of rating changes.

How can I track unusual PCRX options activity related to news?

Unusual options activity often precedes news by hours to days; the canonical signals are volume substantially above the trailing average concentrated in a small number of strikes, atypical put/call skew, and aggressive execution (at-the-ask sweeps or block prints). Cross-reference the per-ticker gamma-exposure and volume-history pages with the news flow above to triangulate informed vs uninformed flow.